Vaccines

BBC NEWS      by Helen Briggs, Environment correspondent                                                                     Feb. 2, 2015

The devastation left by the Ebola virus in west Africa raises many questions for science, policy and international development.

One issue that has yet to receive widespread media attention is the handling of genetic data on the virus.

By studying its code, scientists can trace how Ebola leapt across borders, and how, like all viruses, it is constantly evolving and changing.

Yet, researchers have been privately complaining for months about the scarcity of genetic information about the virus that is entering the public domain.

In the last few days, scientists have been speaking on and off the record about their concerns.

http://www.bbc.com/news/science-environment-31091816

REUTERS   by Kate Kell and Ben Herschler                                                                        Feb. 1. 2015
LONDON --As West Africa's devastating Ebola outbreak begins to dwindle, scientists are looking beyond the endgame at the kind of next-generation vaccines needed for a vital stockpile to hit another epidemic hard and fast.

Determined not to lose scientific momentum that could make the world's first effective Ebola interventions a reality, researchers say the shots, as well as being proven to work, must be cheap, easy to handle in Africa and able to hit multiple virus strains.

That may mean shifting focus from the stripped-down, fast-tracked vaccine development ideas that have dominated the past six months, but it mustn't mean the field gets bogged down in complexities.

Read complete story.

REUTERS by Kate Kelland                                     Jan. 23, 2015

LONDON-- The first batch of GlaxoSmithKline's experimental Ebola vaccine has been shipped to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said.

The shipment, of an initial 300 vials of the vaccine, will be the first to arrive in one of the three main Ebola-affected African countries, GSK said in a statement.

It will be used in the first large-scale vaccine trials in coming weeks, in which healthcare workers helping to care for Ebola patients will be among the first to get it...

The vaccine, co-developed by the National Institutes of Health in the United States and Okairos, a biotechnology firm acquired by GSK in 2013, is currently being tested in five small phase I safety trials in Britain, the United States, Switzerland and Mali involving around 200 healthy volunteers in total.

Read compete story.

http://uk.reuters.com/article/2015/01/23/uk-health-ebola-gsk-idUKKBN0KW0DU20150123

BALTIMORE SUN     by Scott Dance                                                   Jan. 20, 2015

In the year since Ebola began spreading across West Africa, the virus has mutated in more than 600 ways that change it slightly from versions studied in labs and used to develop treatments, according to researchers at Fort Detrick. And 10 of the mutations could make some drugs used to treat the virus ineffective, they wrote in research published Tuesday.

The "genomic drift," as the scientists called it, could make agents similar to the experimental drug ZMapp unable to bind to the virus anymore.

While the changes affect only a tiny fraction of Ebola's genome, they offer new lessons about the virus that might not have been learned because of the wide scope of the outbreak, larger than all others combined
Read complete story.
http://www.baltimoresun.com/health/bs-hs-ebola-mutation-20150120-story.html